International Journal of Medical Sciences
Official Impact Factor

25 May 2017

ISSN 1449-1907 News feeds of published articles

Manuscript Status/Login | Contact

Journal of Genomics now in PubMed/PubMed Central. Submit manuscript...

Journal of Biomedicinenew

Theranostics

Journal of Cancer

Oncomedicine

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2017; 14(1):37-44. doi:10.7150/ijms.17024

Research Paper

Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression

Chun-Wen Su1*, Bo-Feng Su2*, Whei-Ling Chiang3, Shun-Fa Yang1,4, Mu-Kuan Chen1,5, Chiao-Wen Lin6,7✉

1. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
2. Department of Orthopedics, Changhua Christian Hospital, Changhua, Taiwan.
3. School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.
4. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
5. Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan.
6. Institute of Oral Sciences, Chung Shan Medical University, Taichung, Taiwan.
7. Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan.
*These authors contributed equally to the work.

Abstract

Oral cancer is the most common malignancy with poor prognosis and is the fourth most common cancer in men in Taiwan. The tissue inhibitor of metalloproteinase-3 (TIMP3) acts as a tumor suppressor gene by inhibiting the growth, angiogenesis, migration, and invasion of cancer cells. However, few studies have examined the association of plasma TIMP3 levels with oral squamous cell carcinoma (OSCC), and the role of plasma TIMP3 levels in OSCC progression is still unclear. We measured the plasma TIMP3 levels of 450 OSCC patients and 64 healthy controls by using a commercial enzyme-linked immunosorbent assay. We also analyzed TIMP3 mRNA levels of 328 OSCC patients and 32 normal tissues from The Cancer Genome Atlas (TCGA) dataset. Our results revealed that plasma TIMP3 levels were significantly lower in patients with OSCC than in healthy controls (p < 0.001). Moreover, plasma TIMP3 levels in patients with OSCC were significantly associated with the tumor stage and tumor status but not with the lymph node status, metastasis, and cell differentiation. To verify our findings, we also examined TCGA bioinformatics database and discovered similar results for the association with the pathological stage of OSCC. In conclusion, our results suggest that plasma TIMP3 is a potential biomarker for predicting the tumor stage and T status in patients with OSCC.

Keywords: TIMP3, oral squamous cell carcinoma, biomarker.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Su CW, Su BF, Chiang WL, Yang SF, Chen MK, Lin CW. Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression. Int J Med Sci 2017; 14(1):37-44. doi:10.7150/ijms.17024. Available from http://www.medsci.org/v14p0037.htm